Dr. Marty Makary of the FDA discussed the agency's decision to restore access to a Sarepta gene therapy for muscular dystrophy despite safety signals. The conversation on CNBC also touched on the future of mRNA technology, with Makary suggesting it is a "powerful technology" for cancer vaccines. The hosts criticize the FDA's reliance on computational modeling over traditional randomized control trials.
